Composition and capsules containing the same

A combination of ether-type and ester-type glycerophospholipids addresses viscosity and dispersion issues in formulations, ensuring stable and uniform capsule production.

JP7954001B2Active Publication Date: 2026-11-19SUNSHO PHARMA CO LTD
View PDF 11 Cites 0 Cited by

Patent Information

Application Number
JP2022050167
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Filing Date
2022-03-25
Publication Date
2026-11-19
Estimated Expiration
2042-03-25

AI Technical Summary

Technical Problem

Existing formulations using ether-type glycerophospholipids face challenges in achieving suitable viscosity and uniform dispersion, often resulting in precipitate formation when adjusted with edible oils or fats.

Method used

A composition comprising a combination of ether-type and ester-type glycerophospholipids, specifically with ether-type glycerophospholipids like plasmalogen and ester-type glycerophospholipids such as phosphatidylcholine, phosphatidylethanolamine, and phosphatidylinositol, along with optional edible oils or fats, to achieve optimal viscosity and dispersion.

Benefits of technology

The composition achieves suitable viscosity and excellent dispersion uniformity, enabling the production of capsules with improved stability and effectiveness.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007954001000001
    Figure 0007954001000001
  • Figure 0007954001000002
    Figure 0007954001000002
  • Figure 0007954001000003
    Figure 0007954001000003
Patent Text Reader

Abstract

To provide a composition that has suitable viscosity for formulating into capsules and the like and contains ether-based glycerophospholipids.SOLUTION: A composition includes ether-based glycerophospholipids and ester-based glycerophospholipids. The ether-based glycerophospholipids include plasmalogen and the ester-based glycerophospholipids include phosphatidylcholine. The content of the phosphatidylcholine is 10-80 mass% relative to the total mass of the ester-based glycerophospholipids.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] The present invention relates to a composition and a capsule containing the same. [Background technology]

[0002] Phospholipids are a general term for lipids that have phosphate ester bonds in their structure. For example, in living organisms, phospholipids form lipid bilayers, becoming major components of cell membranes and participating in signal transduction. Furthermore, phospholipids are used as surfactants and other substances in fields such as pharmaceuticals and food.

[0003] Phospholipids are broadly classified into glycerophospholipids, which have glycerol as their main backbone, and sphingophospholipids, which have sphingosine as their main backbone. Glycerophospholipids are further classified into ether-type glycerophospholipids and ester-type glycerophospholipids.

[0004] In recent years, plasmalogens, a type of ether-type glycerophospholipid, have attracted attention. For example, Patent Document 1 describes that plasmalogens have a neuronal regeneration effect. [Prior art documents] [Patent Documents]

[0005] [Patent Document 1] International Publication No. 2011 / 083827 [Overview of the Initiative] [Problems that the invention aims to solve]

[0006] When preparing capsules or other formulations using ether-type glycerophospholipids such as plasmalogens, it was sometimes difficult to adjust the viscosity to a level suitable for formulation. Furthermore, adding edible oils or fats to adjust the viscosity sometimes resulted in the formation of precipitates derived from the ether-type glycerophospholipids, leading to insufficient dispersion uniformity.

[0007] Under such circumstances, there is a demand for a composition containing an ether-type glycerophospholipid that has a viscosity suitable for formulation and is excellent in dispersion uniformity. [MEANS FOR SOLVING THE PROBLEMS]

[0008] The present invention includes, for example, the following aspects.

[0009] [1] A composition comprising an ether-type glycerophospholipid and an ester-type glycerophospholipid. [2] The composition according to the above [1], wherein the ether-type glycerophospholipid comprises a plasmalogen. [3] The composition according to the above [1] or [2], wherein the ether-type glycerophospholipid comprises a sea squirt-derived plasmalogen. [4] The ester-type glycerophospholipid comprises phosphatidylcholine, The composition according to any one of the above [1] to [3], wherein the content of the phosphatidylcholine is 10 to 80 mass% relative to the total mass of the ester-type glycerophospholipid. [5] The ester-type glycerophospholipid comprises phosphatidylethanolamine, The composition according to any one of the above [1] to [4], wherein the content of the phosphatidylethanolamine is 5 to 40 mass% relative to the total mass of the ester-type glycerophospholipid. [6] The ester-type glycerophospholipid comprises phosphatidylinositol, The composition according to any one of the above [1] to [5], wherein the content of the phosphatidylinositol is 30 mass% or less relative to the total mass of the ester-type glycerophospholipid. [7] The composition according to any one of the above [1] to [6], wherein the ester-type glycerophospholipid comprises 15 to 22 mass% of phosphatidylcholine, 25 to 32 mass% of phosphatidylethanolamine, and 18 to 25 mass% of phosphatidylinositol. [8] The composition according to any one of the above [1] to [7], wherein the content of the ester-type glycerophospholipid is 1 to 100 parts by mass relative to 1 part by mass of the ether-type glycerophospholipid. [9] The composition according to any one of the above [1] to [8], further comprising an edible oil or fat.

[10] The composition according to the above [9], wherein the content of the edible oil or fat is 100 to 200 parts by mass relative to 1 part by mass of the ether-type glycerophospholipid.

[11] The composition according to any one of the above [1] to

[10] , which has a viscosity of less than 15000 cps.

[12] A capsule comprising: a content comprising the composition according to any one of the above [1] to

[11] , and a film enclosing the content. [Advantageous Effects of Invention]

[0010] According to the present invention, a composition and the like that have a viscosity suitable for formulation and are excellent in dispersion uniformity are provided. [Mode for Carrying Out the Invention]

[0011] Hereinafter, the mode for carrying out the present invention will be described in detail.

[0012] 1 composition The composition according to the present invention comprises an ether-type glycerophospholipid and an ester-type glycerophospholipid. The composition is not particularly limited as long as it comprises the ether-type glycerophospholipid and the ester-type glycerophospholipid, and may further comprise a physiologically active substance, an edible oil or fat, an additive, and the like.

[0013] The composition according to the present invention has a viscosity suitable for formulation and is excellent in dispersion uniformity. Thereby, a capsule or the like comprising the ether-type glycerophospholipid can be suitably produced.

[0014] Hereinafter, each constituent of the composition of the present invention will be described in detail.

[0015] ​[Ether-type glycerophospholipids] Ether-type glycerophospholipids have functions such as those of physiologically active ingredients and surfactants. Their functions as physiologically active ingredients include therapeutic or preventive effects on diseases such as Alzheimer's disease, Parkinson's disease, Down syndrome, multiple sclerosis, and other neurodegenerative diseases; chondrodysplasia punctate; Zellweger spectrum disorders; chronic obstructive pulmonary disease (COPD); arteriosclerosis; liver dysfunction; and dyslipidemia, as well as maintaining memory.

[0016] Ether-type glycerophospholipids are phospholipids in which glycerol is the main backbone, and one or two hydroxyl groups of glycerol form an ether bond with an alcohol. Ether-type glycerophospholipids can be represented, for example, by the following general formulas (1) to (3). Note that general formula (1) has one ether bond at the sn-1 position, general formula (2) has one ether bond at the sn-2 position, and general formula (3) has two ether bonds at the sn-1 and sn-2 positions.

[0017] [ka]

[0018] In the above equations (1) and (2), R 1 Each of these groups is independently derived from a saturated fatty acid or an unsaturated fatty acid. The saturated fatty acid is not particularly limited, but examples include caproic acid, enanthic acid, caprylic acid, lauric acid, myristic acid, palmitic acid, stearic acid, arachidic acid, and behenic acid. The unsaturated fatty acid is an unsaturated fatty acid having one double bond, such as palmitoleic acid and oleic acid; an unsaturated fatty acid having two double bonds, such as linoleic acid; an unsaturated fatty acid having three double bonds, such as linolenic acid; and an unsaturated fatty acid having four or more double bonds, such as arachidonic acid, eicosapentaenoic acid, and docosahexaenoic acid. Of these, the saturated fatty acid is preferably palmitic acid and stearic acid. The unsaturated fatty acid is preferably oleic acid and linoleic acid.

[0019] R 1 Specifically, this refers to a hydrocarbon group having 5 to 30 carbon atoms, preferably an alkyl group having 5 to 30 carbon atoms, an alkenyl group having 5 to 30 carbon atoms, or a cycloalkyl group having 5 to 30 carbon atoms, more preferably an alkyl group having 5 to 30 carbon atoms or an alkenyl group having 5 to 30 carbon atoms, and particularly preferably an alkyl group having 12 to 20 carbon atoms or an alkenyl group having 12 to 25 carbon atoms. In this specification, "alkenyl group" includes those having two or more double bonds (dienes, trienes, tetraenes, pentaenes, hexaenes, etc.).

[0020] While there are no particular limitations on alkyl groups having 5 to 30 carbon atoms, examples include pentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl, tetradecyl, pentadecyl, hexadecyl, heptadecyl, octadecyl, eicosyl, docosyl, tetracosyl, and hexacosyl groups.

[0021] Furthermore, there are no particular restrictions on the alkenyl group having 5 to 30 carbon atoms, but these include pentenyl, hexenyl, heptenyl, octenyl, nonenyl, decenyl, dodecenyl, tetradecenyl, pentadecenyl, hexadecenyl, heptadecenyl, octadecenyl, eicocenyl, dococenyl, tetracocenyl, hexacocenyl, pentadienyl, hexadienyl, heptadecenyl, octadecenyl, nonadienyl, decadienyl, dodecadienyl, tetradecadienyl, pentadecadienyl, and hexadecadienyl. Group, heptadecadienyl group, octadecadienyl group, eicosadienyl group, docosadienyl group, tetracosadienyl group, hexacosadienyl group, pentatrienyl group, hexatrienyl group, heptadecadienyl group, octatrienyl group, nonatrienyl group, decatrienyl group, dodecatrienyl group, tetradecatrienyl group, pentadecadienyl group, hexadecadienyl group, heptadecadienyl group, octadecadienyl group, eicosatrienyl group, docosadrienyl group, tetracosadrienyl group, hexacosatrienyl group, pentatetraenyl group, Hexatetraenyl group, heptatetraenyl group, octatetraenyl group, nonatetraenyl group, decatetraenyl group, dodecatetraenyl group, tetradecatetraenyl group, pentadecatetraenyl group, hexadecatetraenyl group, heptadecatetraenyl group, octadecatetraenyl group, eicosatetraenyl group, docosatetraenyl group, tetracosatetraenyl group, hexacosatetraenyl group, hexapentaenyl group, heptapentaenyl group, octapentaenyl group, nonapentaenyl group, decapentaenyl group, dodecapentaenyl group, tetradecapene Taenyl group, pentadecapentaenyl group, hexadecapentaenyl group, heptadecapentaenyl group, octadecapentaenyl group, nonadecapentaenyl group, eicosapentaenyl group, docosapentaenyl group, tetracosapentaenyl group, hexacosapentaenyl group, heptahexaenyl group, octahexaenyl group, nonahexaenyl group, decahexaenyl group, dodecahexaenyl group, tetradecahexaenyl group, pentadecahexaenyl group, hexadecahexaenyl group, heptadecahexaenyl group, octadecahexaenyl group, nonadecahexaenyl group,Examples include eicosahexaenyl groups, heneicosahexaenyl groups, docosahexaenyl groups, tetracosahexaenyl groups, and hexacosahexaenyl groups.

[0022] Furthermore, while there are no particular limitations on the cycloalkyl groups having 5 to 30 carbon atoms, examples include cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cycloundecyl, cyclododecyl, cyclotetradecyl, cyclopentadecyl, cyclohexadecyl, cycloheptadecyl, cyclooctadecyl, cycloeicosyl, cyclodocosyl, cyclotetracosyl, and cyclohexacosyl groups.

[0023] Note, R 1 If derived from palmitic acid, it is a pentadecyl group; if derived from stearic acid, it is a heptadecyl group; if derived from oleic acid, it is a heptadecenyl group; if derived from linoleic acid, it is a heptadecatrienyl group; if derived from eicosapentaenoic acid, it is a nonadecylpentaenyl group; and if derived from docosahexaenoic acid, it is a heneicosahexaenyl group.

[0024] R, ranked 1st in sn- 1 It is preferably an alkyl group having 5 to 30 carbon atoms, more preferably an alkyl group having 12 to 20 carbon atoms, and even more preferably a pentadecyl group or a heptadecyl group. Also, the R at the sn-2 position 1 It is preferably an alkenyl group having 5 to 30 carbon atoms, more preferably an alkenyl group having 12 to 25 carbon atoms, even more preferably a heptadecenyl group, a heptadecatrienyl group, a nonadecylpentaenyl group, or a heneicosahexaenyl group, particularly preferably a nonadecylpentaenyl group or a heneicosahexaenyl group, and most preferably a heneicosahexaenyl group.

[0025] In the above equations (1) to (3), R 2are each independently a hydrocarbon group having 5 to 30 carbon atoms, preferably an alkyl group having 5 to 30 carbon atoms, an alkenyl group having 5 to 30 carbon atoms, or a cycloalkyl group having 5 to 30 carbon atoms, more preferably an alkyl group having 5 to 30 carbon atoms or an alkenyl group having 5 to 30 carbon atoms, and particularly preferably an alkyl group having 12 to 20 carbon atoms or an alkenyl group having 12 to 20 carbon atoms. Specific examples of the alkyl group having 5 to 30 carbon atoms, the alkenyl group having 5 to 30 carbon atoms, and the cycloalkyl group having 5 to 30 carbon atoms are the same as those for R 1 described above. In this case, R at the sn-1 position 2 is preferably an alkyl group having 5 to 30 carbon atoms, more preferably an alkyl group having 12 to 20 carbon atoms, and even more preferably a pentadecyl group or a heptadecyl group. Further, R at the sn-2 position 2 is preferably an alkenyl group having 5 to 30 carbon atoms, more preferably an alkenyl group having 12 to 25 carbon atoms, and even more preferably a heptadecenyl group or a heptadecatrienyl group.

[0026] In the above formulas (1) to (3), X is a group derived from choline, ethanolamine, serine, or inositol. For example, when X is derived from choline, it is -CH₂CH₂N(CH₃)₃ + , and when X is derived from ethanolamine, it is -CH₂CH₂NH₃ + . X is preferably -CH₂CH₂N(CH₃)₃ + or -CH₂CH₂NH₃ + , and more preferably -CH₂CH₂NH₃ + .

[0027] The ether-type glycerophospholipid contained in the composition of the present invention is preferably a compound represented by general formula (1), and more preferably a compound represented by the following general formula (4) having a vinyl ether bond at the sn-1 position. In the present specification, the ether-type glycerophospholipid represented by general formula (4) may be referred to as "plasmalogen". That is, in a preferred embodiment, the ether-type glycerophospholipid contains plasmalogen.

[0028] [ka]

[0029] In formula (4), R 1 And X is R in equation (1). 1 And it is the same as X.

[0030] In formula (4), R 3 This is a hydrocarbon group having 3 to 28 carbon atoms, preferably an alkyl group having 3 to 28 carbon atoms or an alkenyl group having 3 to 28 carbon atoms, more preferably an alkyl group having 3 to 28 carbon atoms or an alkenyl group having 3 to 28 carbon atoms, and particularly preferably an alkyl group having 10 to 18 carbon atoms or an alkenyl group having 10 to 18 carbon atoms.

[0031] The alkyl group having 3 to 28 carbon atoms is not particularly limited, but examples include propyl group, butyl group, pentyl group, hexyl group, heptyl group, octyl group, nonyl group, decyl group, undecyl group, dodecyl group, tetradecyl group, pentadecyl group, hexadecyl group, heptadecyl group, octadecyl group, eicosyl group, docosyl group, tetracosyl group, and hexacosyl group.

[0032] Furthermore, there are no particular restrictions on the alkenyl group having 3 to 28 carbon atoms, but the following are acceptable: propenyl, butenyl, pentenyl, hexenyl, heptenyl, octenyl, nonenyl, decenyl, dodecenyl, tetradecenyl, pentadecenyl, hexadecenyl, heptadecenyl, octadecenyl, eicocenyl, dococenyl, tetracocenyl, hexacocenyl, propadienyl, butadienyl, and pentadecenyl. Ntadienyl group, hexadienyl group, heptadienyl group, octadienyl group, nonadienyl group, decadienyl group, dodecadienyl group, tetradecadienyl group, pentadecadienyl group, hexadecadienyl group, heptadecadienyl group, octadecadienyl group, eicosadienyl group, docosadienyl group, tetracosadienyl group, hexacosadienyl group, propatotrienyl group, butatrienyl group, pentatrienyl group, hexa Trienyl group, heptatrienyle group, octatrienyl group, nonatrienyl group, decatrienyl group, dodecatrienyle group, tetradecatrienyle group, pentadecatrienyl group, hexadecatrienyl group, heptadecatrienyl group, octadecatrienyl group, eicosatrienyl group, docosatrienyl group, tetracosatrienyl group, hexacosatrienyl group, propatetraenyl group, butatetraenyl group, pentatetraenyl Examples include the nyl group, hexatetraenyl group, heptatetraenyl group, octatetraenyl group, nonatetraenyl group, decatetraenyl group, dodecatetraenyl group, tetradecatetraenyl group, pentadecatetraenyl group, hexadecatetraenyl group, heptadecatetraenyl group, octadecatetraenyl group, eicosatetraenyl group, docosatetraenyl group, tetracosatetraenyl group, hexacosatetraenyl group, and the like.

[0033] R 3 The group is preferably an alkyl group having 3 to 28 carbon atoms, preferably an alkyl group having 10 to 18 carbon atoms, more preferably a tetradecyl group, a hexadecyl group, a hexadecenyl group, or a hexadecatriaenyl group, even more preferably a tetradecyl group or a hexadecyl group, and particularly preferably a hexadecyl group.

[0034] In formula (4), R1 It is preferably a pentadecyl group, a heptadecyl group, a heptadecenyl group, a heptadecatetrienyl group, a nonadecylpentaenyl group, or a heneicosahexaenyl group; more preferably a heptadecyl group, a nonadecylpentaenyl group, or a heneicosahexaenyl group; even more preferably a nonadecylpentaenyl group, a heneicosahexaenyl group, or a heneicosahexaenyl group; and particularly preferably a heneicosahexaenyl group. Also, R 3 X is preferably a tetradecyl group, a hexadecyl group, a hexadecenyl group, or a hexadecatetrienyl group, and more preferably a hexadecyl group. X is -CH2CH2N(CH3)3 + -CH2CH2NH3 + It is preferable that it be -CH2CH2NH3 + It is more preferable that R 1 R is a heterocosahexaenyl group, 3 is a hexadecyl group, and X is -CH2CH2NH3 + That is the case.

[0035] In this specification, ether-type plasmalogens may include ester hydrolysates represented by the following general formulas (5) to (6); phosphate ester hydrolysates represented by the following general formulas (7) to (9); and ester and phosphate ester hydrolysates represented by the following general formulas (10) to (11).

[0036] [ka]

[0037] In formulas (5) to (11), R 1 , R 2 , and X are R in equations (1) and (2). 1 , R 2 , and is the same as X.

[0038] The ether-type glycerophospholipids described above may be used individually or in combination of two or more types.

[0039] Ether-type glycerophospholipids can be obtained by extraction from, for example, mammals such as chickens, cattle, pigs, horses, sheep, deer, camels, and ducks; fish and shellfish such as sea squirts, sea urchins, shrimp, turban shells, oysters, and scallops; and bacteria such as Acidamino coccaceae. Of these, ether-type glycerophospholipids are preferably those containing plasmalogens derived from fish and shellfish, from the viewpoint of containing a large amount of groups derived from eicosapentaenoic acid and docosahexaenoic acid at the sn-2 position, and more preferably those containing plasmalogens derived from sea squirts, from the viewpoint of containing a large amount of groups derived from docosahexaenoic acid at the sn-2 position.

[0040] The content of ether-type glycerophospholipids is preferably 0.01 to 20% by mass, more preferably 0.01 to 15% by mass, even more preferably 0.01 to 10% by mass, even more preferably 0.01 to 5% by mass, and particularly preferably 0.01 to 2.5% by mass, based on the total mass of the composition. If the composition contains two or more types of ether-type glycerophospholipids, it is preferable that their total amount falls within the above range.

[0041] [Ester-type glycerophospholipids] Ester-type glycerophospholipids have functions such as adjusting the viscosity of compositions containing ether-type glycerophospholipids, suppressing precipitate formation, and suppressing bubble generation.

[0042] Ester-type glycerophospholipids are phospholipids in which glycerol is the main backbone, and the two hydroxyl groups of glycerol form ester bonds with fatty acids. Ester-type glycerophospholipids can be represented, for example, by the following general formula (12).

[0043] [ka]

[0044] In formula (12), R 1 And X is R in equations (1) and (2). 1, and the same applies to X. In this case, the sn-1 R 1 It is preferably an alkyl group having 5 to 30 carbon atoms, more preferably an alkyl group having 12 to 20 carbon atoms, and even more preferably a pentadecyl group or a heptadecyl group. Also, the R at the sn-2 position 1 It is preferably an alkenyl group having 5 to 30 carbon atoms, more preferably an alkenyl group having 12 to 20 carbon atoms, and even more preferably a heptadecenyl group or a heptadecatrienyl group.

[0045] Of the above, the ester-type glycerophospholipid preferably contains at least one selected from the group consisting of phosphatidylcholine, phosphatidylethanolamine, phosphatidylinositol, and phosphatidylserine, and more preferably contains at least one selected from the group consisting of phosphatidylcholine, phosphatidylethanolamine, and phosphatidylinositol.

[0046] In this specification, ester-type glycerophospholipids may include ester hydrolysates represented by the following general formulas (13) to (15); phosphate ester hydrolysates represented by the following general formula (16); and ester and phosphate ester hydrolysates represented by the following general formulas (17) to (19). Note that the ester hydrolysate represented by general formula (14) is referred to as "lysoester-type glycerophospholipid," the phosphate ester hydrolysate represented by general formula (16) is referred to as "phosphatidic acid," and the ester and phosphate ester hydrolysate represented by general formula (18) is referred to as "lysophosphatidic acid."

[0047] [ka]

[0048] In formulas (13) to (19), R 1 And X is R in equation (12). 1 , and is the same as X.

[0049] The ester-type glycerophospholipids described above may be used individually or in combination of two or more types.

[0050] When the ester-type glycerophospholipid contains phosphatidylcholine (PC), the phosphatidylcholine content is preferably 10 to 80% by mass, more preferably 10 to 60% by mass, even more preferably 10 to 30% by mass, and particularly preferably 15 to 22% by mass, based on the total mass of the ester-type glycerophospholipid. In one embodiment, when the ester-type glycerophospholipid contains phosphatidylcholine (PC), the phosphatidylcholine content is preferably 10 to 60% by mass, more preferably 15 to 40% by mass, even more preferably 20 to 40% by mass, and particularly preferably 24 to 32% by mass, based on the total mass of the ester-type glycerophospholipid. Furthermore, in one embodiment, if the ester-type glycerophospholipid contains phosphatidylcholine (PC), the phosphatidylcholine content is preferably 30 to 90% by mass, more preferably 45 to 85% by mass, even more preferably 60 to 80% by mass, and particularly preferably 65 to 75% by mass, based on the total mass of the ester-type glycerophospholipid. In this specification, "total mass of ester-type glycerophospholipid" includes esters and / or phosphate ester hydrolysates of ester-type glycerophospholipids represented by general formulas (13) to (19).

[0051] When the ester-type glycerophospholipid contains phosphatidylethanolamine (PE), the phosphatidylethanolamine content is preferably 5 to 40% by mass, more preferably 20 to 40% by mass, and even more preferably 25 to 32% by mass, based on the total mass of the ester-type glycerophospholipid. In one embodiment, when the ester-type glycerophospholipid contains phosphatidylethanolamine (PE), the phosphatidylethanolamine content is preferably 10 to 40% by mass, more preferably 15 to 35% by mass, and even more preferably 20 to 28% by mass, based on the total mass of the ester-type glycerophospholipid. In one embodiment, when the ester-type glycerophospholipid contains phosphatidylethanolamine (PE), the phosphatidylethanolamine content is preferably 1 to 40% by mass, more preferably 3 to 30% by mass, even more preferably 5 to 20% by mass, and particularly preferably 10 to 15% by mass, based on the total mass of the ester-type glycerophospholipid.

[0052] When the ester-type glycerophospholipid contains phosphatidylinositol (PI), the phosphatidylinositol content is preferably 30% by mass or less, more preferably 5 to 30% by mass, even more preferably 10 to 30% by mass, and particularly preferably 18 to 25% by mass, based on the total mass of the ester-type glycerophospholipid. In one embodiment, when the ester-type glycerophospholipid contains phosphatidylinositol (PI), the phosphatidylinositol content is preferably 3 to 40% by mass, more preferably 5 to 30% by mass, even more preferably 10 to 25% by mass, and particularly preferably 12 to 20% by mass, based on the total mass of the ester-type glycerophospholipid. Furthermore, in one embodiment, when the ester-type glycerophospholipid contains phosphatidylinositol (PI), the phosphatidylinositol content is preferably 20% by mass or less, more preferably 10% by mass or less, even more preferably 0.001 to 5% by mass, and particularly preferably 0.01 to 1% by mass, relative to the total mass of the ester-type glycerophospholipid.

[0053] Ester-type glycerophospholipids preferably contain phosphatidylcholine (PC), phosphatidylethanolamine (PE), and phosphatidylinositol (PI), more preferably containing 10-30% by mass of phosphatidylcholine, 20-40% by mass of phosphatidylethanolamine, and 10-30% by mass of phosphatidylinositol based on the total mass of the ester-type glycerophospholipids, and even more preferably containing 15-22% by mass of phosphatidylcholine, 25-32% by mass of phosphatidylethanolamine, and 18-25% by mass of phosphatidylinositol. In one embodiment, the ester-type glycerophospholipid preferably contains phosphatidylcholine (PC), phosphatidylethanolamine (PE), and phosphatidylinositol (PI), more preferably containing 20-40% by mass of phosphatidylcholine, 15-35% by mass of phosphatidylethanolamine, and 10-25% by mass of phosphatidylinositol based on the total mass of the ester-type glycerophospholipid, and even more preferably containing 24-32% by mass of phosphatidylcholine, 20-28% by mass of phosphatidylethanolamine, and 12-20% by mass of phosphatidylinositol. Furthermore, in one embodiment, the ester-type glycerophospholipid preferably contains phosphatidylcholine (PC), phosphatidylethanolamine (PE), and phosphatidylinositol (PI), more preferably containing 60-80% by mass of phosphatidylcholine, 15-20% by mass of phosphatidylethanolamine, and 0.001-5% by mass of phosphatidylinositol based on the total mass of the ester-type glycerophospholipid, and even more preferably containing 65-75% by mass of phosphatidylcholine, 10-15% by mass of phosphatidylethanolamine, and 0.01-1% by mass of phosphatidylinositol.

[0054] Ester-type glycerophospholipids can be obtained by extraction from chicken eggs, soybeans, rapeseed, beef, etc. These ester-type glycerophospholipids are sometimes called lecithin and are typically mixtures mainly composed of ester-type glycerophospholipids. Soybean lecithin and egg yolk lecithin are preferred, with soybean lecithin being more preferred. The composition of ester-type glycerophospholipids in lecithin can be appropriately adjusted, for example, by selecting raw materials, extraction methods, and purification methods.

[0055] Ester-type glycerophospholipids may be commercially available. There are no particular restrictions on commercially available new products, but examples include J-Lecithin CL (manufactured by J-Oil Mills Co., Ltd.), SLP-PI Powder, SLP-PC70, and SLP-White (manufactured by Tsuji Oil Co., Ltd.).

[0056] The content of ester-type glycerophospholipids is preferably 0.1 to 50% by mass, more preferably 0.1 to 25% by mass, and even more preferably 0.1 to 12.5% ​​by mass, based on the total mass of the composition. If the composition contains two or more types of ester-type glycerophospholipids, it is preferable that their total amount falls within the above range.

[0057] Furthermore, the content of ester-type glycerophospholipids is preferably 0.1 to 500 parts by mass, more preferably 0.5 to 300 parts by mass, even more preferably 0.8 to 200 parts by mass, even more preferably 0.9 to 150 parts by mass, and particularly preferably 1 to 100 parts by mass, per 1 part by mass of ether-type glycerophospholipids, and may also be 1 to 75 parts by mass, 1 to 30 parts by mass, 1 to 20 parts by mass, or 1 to 10 parts by mass. A content of ester-type glycerophospholipids of 0.1 parts by mass or more is preferable from the viewpoint of being able to adjust the viscosity of the composition to a suitable level and suppress the formation of precipitates. On the other hand, a content of ester-type glycerophospholipids of 500 parts by mass or less is preferable from the viewpoint of being able to suppress the generation of bubbles.

[0058] [Physiologically active substances] In a composition of a preferred embodiment of the present invention, ether-type glycerophospholipids such as plasmalogens may be used as an active ingredient or as an additive such as a surfactant, as described above. When ether-type glycerophospholipids are used as an active ingredient in a composition of a preferred embodiment of the present invention, the composition may further contain a physiologically active substance. Furthermore, when ether-type glycerophospholipids are used as an additive such as a surfactant in a composition of a preferred embodiment of the present invention, it is preferable that the composition contains a physiologically active substance.

[0059] The physiologically active substances that may be included in the composition of the present invention are not particularly limited, and known substances can be used. Specific examples of physiologically active substances include, for example, vitamin A, vitamin B, vitamin C, vitamin D, and vitamin E. In this case, the physiologically active substances may be used individually or in combination of two or more. The content of the physiologically active substance in the composition of the present invention is preferably 0.01 to 50% by mass, and more preferably 0.03 to 50% by mass, based on the total mass of the composition.

[0060] [Edible oils and fats] The composition of the present invention may contain edible oils and fats. Edible oils and fats have functions such as adjusting the viscosity of the composition and dispersing the components in the composition.

[0061] Edible oils and fats are not particularly limited, but examples include animal and vegetable oils and medium-chain triglycerides.

[0062] Examples of the aforementioned animal and vegetable oils include olive oil, sesame oil, wheat germ oil, safflower oil, perilla oil, soybean oil, camellia oil, corn oil, peppermint oil, castor oil, cottonseed oil, coconut oil, peanut oil, fish oil, egg yolk oil, beef tallow, lard, beeswax, bleached beeswax, carnauba wax, and lanolin.

[0063] The aforementioned medium-chain fatty acid triglycerides are not particularly limited, but examples include glyceryl tricaprylate, glyceryl tri(caprylic / capric acid), glyceryl tri(caprylic / capric acid / lauric acid), and glyceryl tri(caprylic / capric acid). Commercially available medium-chain fatty acid triglycerides include Coconad RK (glyceryl tricaprylate), Coconad MT (tri(caprylic / capric acid) glyceryl), Coconad ML (tri(caprylic / capric acid / lauric acid) glyceryl (manufactured by Kao Corporation); ODO (tri(caprylic / capric acid) glyceryl (manufactured by Nisshin Oillio Group Ltd.)). In this specification, "medium-chain fatty acid" refers to saturated fatty acids with 5 to 12 carbon atoms, unsaturated fatty acids with 5 to 12 carbon atoms, preferably saturated fatty acids with 8 to 10 carbon atoms, and unsaturated fatty acids with 8 to 10 carbon atoms. Furthermore, "medium-chain fatty acid triglyceride" refers to a compound in which two or three medium-chain fatty acids are ester-bonded to glycerin. In one embodiment, the medium-chain fatty acid triglyceride is a mixture of non-volatile oily compounds obtained by pressing the kernels of seeds such as coconuts and palms.

[0064] The edible oils and fats mentioned above may be used individually or in combination of two or more types.

[0065] The edible oil content is preferably 25 to 99% by mass, and more preferably 50 to 99% by mass, based on the total mass of the composition. If the composition contains two or more types of edible oils, it is preferable that their total amount falls within the above range.

[0066] Furthermore, the content of edible oils and fats is preferably 10 to 300 parts by mass, more preferably 100 to 250 parts by mass, even more preferably 130 to 225 parts by mass, particularly preferably 160 to 220 parts by mass, and may also be 180 to 210 parts by mass, 190 to 200 parts by mass, or 190 to 199.5 parts by mass per 1 part by mass of the ether-type glycerophospholipid. When the content of edible oils and fats is 10 parts by mass or more per 1 part by mass of the ether-type glycerophospholipid, it is preferable from the viewpoint of being able to suppress the generation of bubbles. On the other hand, when the content of edible oils and fats is 300 parts by mass or less per 1 part by mass of the ether-type glycerophospholipid, it is preferable from the viewpoint of being able to adjust the viscosity of the composition to a suitable level and suppress the formation of precipitates.

[0067] [Additives] The compositions of the present invention may contain additives. The additives included in the compositions of the present invention are not particularly limited, but examples include excipients, wetting agents, thickeners, preservatives, stabilizers, coating agents, pH adjusters, and fragrances. These additives may be used individually or in combination of two or more.

[0068] [Physical properties of the composition] The viscosity of the composition according to the present invention is preferably less than 15,000 cps, more preferably less than 14,000 cps, even more preferably less than 13,000 cps, even more preferably less than 12,000 cps, even more preferably less than 11,000 cps, even more preferably less than 10,000 cps, even more preferably less than 9,000 cps, and particularly preferably less than 8,000 cps. Furthermore, the viscosity of the composition according to the present invention is preferably 500 cps or more, more preferably 750 cps or more, even more preferably 1,000 cps or more, even more preferably 2,000 cps or more, and particularly preferably 3,000 cps or more. The viscosity of the composition according to the present invention is preferably 500 cps or more and less than 15,000 cps, more preferably 750 cps or more and less than 12,000 cps, and even more preferably 1,000 cps or more and less than 8,000 cps. A viscosity of less than 15,000 cps of the composition is suitable for formulation from the viewpoint of fluidity, etc. In this specification, "viscosity" is measured by the method described in the examples.

[0069] The proportion of precipitate in the composition according to the present invention is preferably less than 0.3% by mass, more preferably less than 0.2% by mass, even more preferably less than 0.1% by mass, even more preferably less than 0.08% by mass, and particularly preferably less than 0.05% by mass. Furthermore, the lower limit of the proportion of precipitate in the composition according to the present invention is not particularly limited, but may be 0.001% by mass or more, 0.003% by mass or more, 0.005% by mass or more, 0.01% by mass or more, or 0.05% by mass or more. The proportion of precipitate in the composition according to the present invention is preferably less than 0.3% by mass, more preferably 0.001% by mass or more and less than 0.2% by mass, even more preferably 0.005% by mass or more and less than 0.1% by mass, and particularly preferably 0.01% by mass or more and less than 0.08% by mass. A proportion of precipitate in the composition of less than 0.3% is preferable because the components contained in the composition can be uniformly dispersed. In this specification, "precipitate" means a precipitate containing precipitated ether-type glycerophospholipids as its main component. In this case, the precipitate contains 50% by mass or more, preferably 60% by mass or more, and more preferably 70% by mass or more of ether-type glycerophospholipids, based on the total mass of the precipitate. The precipitate may further contain components derived from the raw materials of the ether-type glycerophospholipids, such as oils, proteins, metals, etc. In this specification, the "percentage of precipitate" is measured by the method described in the examples.

[0070] The preferred composition of the present invention is less likely to produce bubbles. The percentage of bubbles generated by bubbling the composition according to the present invention is preferably less than 0.6% by mass, more preferably less than 0.5% by mass, even more preferably less than 0.3% by mass, even more preferably less than 0.2% by mass, and particularly preferably less than 0.1% by mass. The lower limit of the percentage of bubbles generated by bubbling the composition according to the present invention is not particularly limited, but may be 0.001% by mass or more, 0.003% by mass or more, 0.005% by mass or more, or 0.01% by mass or more. The percentage of bubbles generated by bubbling the composition according to the present invention is preferably less than 0.6% by mass, more preferably 0.001% by mass or more and less than 0.5% by mass, even more preferably 0.005% by mass or more and less than 0.2% by mass, and particularly preferably 0.01% by mass or more and less than 0.1% by mass. A percentage of bubbles generated by bubbling the composition of less than 0.6% by mass is preferable because it makes it difficult for bubbles to form in the composition and prevents the formation of bubbles in the capsule contents. In this specification, the "percentage of bubbles generated by bubbling" is measured by the method described in the examples.

[0071] 2. Capsules According to one embodiment of the present invention, a capsule is provided. The capsule comprises a content containing the above-mentioned composition and a coating that encloses the content. Examples of the capsule include soft capsules, hard capsules, seamless capsules, and the like.

[0072] [Contents] The contents of the capsule preparation of the present invention include the composition of the present invention.

[0073] The content of the contents is preferably 30 to 90% by mass, and more preferably 40 to 80% by mass, relative to the total mass of the capsule.

[0074] [coating] The coating constituting the capsule of the present invention is not particularly limited, but it is preferable to include a gelling agent and additives.

[0075] (Gelling agent) Examples of gelling agents are not particularly limited, but include gelatin, carrageenan, agar, sodium alginate, pullulan, glucomannan, gum arabic, pullulan, gellan gum, xanthan gum, gellan gum, tragacanth gum, pectin, glucomannan, starch, polydextrose, dextrin, maltodextrin, cyclodextrin, indigestible dextrin, guar gum, psyllium seed gum, hydroxypropyl cellulose, hydroxypropyl methylcellulose, methylcellulose, carboxymethylcellulose, chitosan, casein, etc. These gelling agents may be used alone or in combination of two or more.

[0076] (Additives) The aforementioned film may contain additives. These additives are not particularly limited, but examples include plasticizers, colorants, sweeteners, flavorings, antioxidants, and preservatives. These additives may be used individually or in combination of two or more.

[0077] The coating content is preferably 10 to 70% by mass, and more preferably 20 to 60% by mass, relative to the total mass of the capsule.

[0078] 3. Other preparations According to one embodiment of the present invention, a formulation other than a capsule is provided. The formulation other than a capsule is not particularly limited, but examples include tablets, suppositories, ointments, patches, suspensions, emulsions, liquids, syrups, etc. In this case, the additives used are appropriately selected according to the type of formulation.

[0079] 4. Manufacturing method The composition of the present invention can be produced by mixing ether-type glycerophospholipids and ester-type glycerophospholipids, and preferably by dissolving one or more selected from the group consisting of ether-type glycerophospholipids and ester-type glycerophospholipids in edible oils and fats.

[0080] 5.Applications In one embodiment, the above-described capsules and other formulations can be used for applications such as pharmaceuticals, quasi-drugs, foods, supplements, foods for specified health uses, foods with functional claims, and foods with nutritional function claims. [Examples]

[0081] The present invention will be specifically described below with reference to examples, but the present invention is not limited to these examples.

[0082] [Raw materials] SLP-PI powder (PE / PI fractionated lecithin), SLP-White (high-purity powdered lecithin), and SLP-PC70 (PC fractionated lecithin) were prepared. Their specific compositions are shown in Table 1 below.

[0083] [Table 1]

[0084] Furthermore, the sn-1 position of phosphatidylcholine (PC) is derived from palmitic acid, and the sn-2 position is derived from oleic acid. The sn-1 position of phosphatidylethanolamine (PE) is derived from palmitic acid, and the sn-2 position is derived from oleic acid. The sn-1 position of phosphatidylinositol (PI) is derived from stearic acid, and the sn-2 position is derived from arachidonic acid.

[0085] [Example 1] The composition was prepared by dissolving 189 parts by mass of ODO (manufactured by Nisshin Oillio Group Ltd.), a medium-chain triglyceride (MCT), with 10 parts by mass of SLP-PI powder (PE·PI fractionated lecithin) at room temperature (25°C), and then adding 100 parts by mass of plasmalogen oil derived from sea squirts (1% by mass, manufactured by Nippon Yakuhin Co., Ltd.) (amount added as plasmalogen: 1 part by mass). The plasmalogen contained in the plasmalogen oil is R in general formula (4). 1 This is a group derived from docosahexaenoic acid (a hemolytic cosahexaenyl group), and R 3 is a hexadecyl group, and X is -CH2CH2NH3 + It is a compound represented by [formula].

[0086] [Example 2] The composition was prepared in the same manner as in Example 1, except that SLP-White (high-purity powdered lecithin) was used instead of SLP-PI powder.

[0087] [Example 3] The composition was prepared in the same manner as in Example 1, except that SLP-PC70 (PC fractionated lecithin) was used instead of SLP-PI powder.

[0088] [Example 4] The composition was prepared in the same manner as in Example 1, except that the amount of medium-chain triglyceride (MCT) added was changed to 198 parts by mass and the amount of SLP-PI powder added was changed to 1 part by mass.

[0089] [Example 5] The composition was prepared in the same manner as in Example 1, except that the amount of medium-chain triglyceride (MCT) added was changed to 174 parts by mass and the amount of SLP-PI powder added was changed to 25 parts by mass.

[0090] [Example 6] The composition was prepared in the same manner as in Example 1, except that the amount of medium-chain triglyceride (MCT) added was changed to 149 parts by mass and the amount of SLP-PI powder added was changed to 50 parts by mass.

[0091] [Example 7] The composition was prepared in the same manner as in Example 1, except that the amount of medium-chain triglyceride (MCT) added was changed to 99 parts by mass and the amount of SLP-PI powder added was changed to 100 parts by mass.

[0092] [Comparative Example 1] The composition was prepared by adding 100 parts by mass of plasmalogen oil (1% by mass) derived from sea squirts (amount added as plasmalogen: 1 part by mass) to 199 parts by mass of medium-chain triglyceride (MCT) and dissolving it at room temperature (25°C).

[0093] [Comparative Example 2] A composition was prepared by adding 179 parts by mass of medium-chain triglyceride (MCT) to 100 parts by mass of sea squirt-derived plasmalogen oil (1% by mass) (amount added as plasmalogen: 1 part by mass) and 20 parts by mass of refined beeswax SS (manufactured by Yokozeki Oil & Fat Industry Co., Ltd.), and dissolving it at 60°C.

[0094] The compositions of the compositions prepared in Examples 1-7 and Comparative Examples 1-2 are shown in Table 2 below.

[0095] [Table 2]

[0096] [evaluation] The compositions prepared in Examples 1-7 and Comparative Examples 1-2 were evaluated in various ways.

[0097] (Viscosity evaluation) Under conditions of 25°C, 60 mL of the composition was transferred to a tall beaker (100 mL capacity), and the viscosity (25°C) was measured using a BROOKFIELD DV-E VISCOMETER at a speed of 12 rpm and spindle LV-2 (62). The viscosity was evaluated according to the following criteria. The results are shown in Table 3 below.

[0098] A: Less than 8000 cps B: 8000 cps or more, less than 15000 cps C:15000cps or more

[0099] (Precipitation evaluation) Under conditions of 25°C, 13 mL of the composition was transferred to a centrifuge tube (15 mL capacity), and its mass was precisely measured to determine the sample mass. Next, a first centrifugation was performed at 1000 × g for 10 minutes, and the supernatant was removed. A second centrifugation was performed again at 1000 × g for 10 minutes, and after removing the supernatant, 2 mL of medium-chain triglyceride (MCT) was added to the centrifuge tube to wash the precipitate. A first centrifugation was then performed at 1000 × g for 10 minutes, the supernatant was removed, and its mass was precisely measured to determine the amount of precipitate. The proportion of precipitate in the composition was calculated using the following formula.

[0100] Percentage of precipitate (mass %) = Amount of precipitate / Mass of sample × 100

[0101] The precipitate was evaluated according to the following criteria based on its proportion. The results are shown in Table 3 below.

[0102] A: Less than 0.2% by mass B: 0.2% by mass or more and less than 0.3% by mass C: 0.3% by mass or more

[0103] (Bubble evaluation) Under conditions of 25°C, the composition was precisely weighed into a 20 mL volumetric flask, taking care to avoid introducing air bubbles, and its mass (g / 20 mL) was measured. The composition was bubbling with air at 1 L / min for 10 minutes to mix the air into the composition. The bubbling mixture was then accurately weighed into a 20 mL volumetric flask, and its mass (g / 20 mL) was measured. The proportion of bubbles in the composition after bubbling was calculated using the following formula.

[0104] Bubble percentage (mass %) = (mass before bubbling - mass after bubbling) / mass after bubbling × 100

[0105] The proportion of air bubbles was evaluated according to the following criteria. The results are shown in Table 3 below.

[0106] A: Less than 0.2% by mass B: 0.2% by mass or more and less than 0.6% by mass C: 0.6% by mass or more

[0107] [Table 3]

[0108] The results in Table 3 show that the compositions produced in Examples 1-7 had low viscosity and little precipitate, indicating excellent viscosity and dispersion uniformity suitable for formulation. In contrast, the composition produced in Comparative Example 1 had a high proportion of precipitate and poor dispersion uniformity, and the composition produced in Comparative Example 2 had too high a viscosity, making formulation difficult.

Claims

1. It contains ether-type glycerophospholipids and ester-type glycerophospholipids. The aforementioned ester-type glycerophospholipid contains phosphatidylinositol, The phosphatidylinositol content is 30% by mass or less relative to the total mass of the ester-type glycerophospholipid. A composition in which the content of the ester-type glycerophospholipid is 1 to 100 parts by mass per 1 part by mass of the ether-type glycerophospholipid.

2. comprising an ether-type glycerophospholipid, an ester-type glycerophospholipid, and an edible oil and fat, The aforementioned ester-type glycerophospholipid contains phosphatidylinositol, The phosphatidylinositol content is 30% by mass or less relative to the total mass of the ester-type glycerophospholipid. A composition in which the content of the edible oil is 100 to 200 parts by mass per 1 part by mass of the ether-type glycerophospholipid.

3. comprising an ether-type glycerophospholipid and an ester-type glycerophospholipid, The aforementioned ester-type glycerophospholipid contains phosphatidylinositol, The phosphatidylinositol content is 30% by mass or less relative to the total mass of the ester-type glycerophospholipid. A composition having a viscosity of less than 15,000 cps.

4. The composition according to any one of claims 1 to 3, wherein the ether-type glycerophospholipid comprises a plasmalogen.

5. The composition according to any one of claims 1 to 4, wherein the ether-type glycerophospholipid comprises a plasmalogen derived from a sea squirt.

6. The aforementioned ester-type glycerophospholipid contains phosphatidylcholine, The composition according to any one of claims 1 to 5, wherein the phosphatidylcholine content is 10 to 80% by mass relative to the total mass of the ester-type glycerophospholipid.

7. The ester-type glycerophospholipid contains phosphatidylethanolamine, The composition according to any one of claims 1 to 6, wherein the content of the phosphatidylethanolamine is 5 to 40% by mass relative to the total mass of the ester-type glycerophospholipid.

8. comprising an ether-type glycerophospholipid and an ester-type glycerophospholipid, The aforementioned ether-type glycerophospholipid contains plasmalogen derived from sea squirts, The aforementioned ester-type glycerophospholipid contains phosphatidylcholine, The phosphatidylcholine content is 10 to 80% by mass relative to the total mass of the ester-type glycerophospholipid. A composition in which the content of the ester-type glycerophospholipid is 1 to 100 parts by mass per 1 part by mass of the ether-type glycerophospholipid.

9. comprising an ether-type glycerophospholipid and an ester-type glycerophospholipid, The aforementioned ether-type glycerophospholipid contains plasmalogen derived from sea squirts, The ester-type glycerophospholipid contains phosphatidylethanolamine, The content of the phosphatidylethanolamine is 5 to 40% by mass relative to the total mass of the ester-type glycerophospholipid. A composition in which the content of the ester-type glycerophospholipid is 1 to 100 parts by mass per 1 part by mass of the ether-type glycerophospholipid.

10. comprising an ether-type glycerophospholipid, an ester-type glycerophospholipid, and an edible oil and fat, The aforementioned ether-type glycerophospholipid contains plasmalogen derived from sea squirts, The aforementioned ester-type glycerophospholipid contains phosphatidylcholine, The phosphatidylcholine content is 10 to 80% by mass relative to the total mass of the ester-type glycerophospholipid. A composition in which the content of the edible oil is 100 to 200 parts by mass per 1 part by mass of the ether-type glycerophospholipid.

11. comprising ether-type glycerophospholipid, ester-type glycerophospholipid, and edible oil and fat, The aforementioned ether-type glycerophospholipid contains plasmalogen derived from sea squirts, The ester-type glycerophospholipid contains phosphatidylethanolamine, The content of the phosphatidylethanolamine is 5 to 40% by mass relative to the total mass of the ester-type glycerophospholipid. A composition in which the content of the edible oil is 100 to 200 parts by mass per 1 part by mass of the ether-type glycerophospholipid.

12. comprising an ether-type glycerophospholipid and an ester-type glycerophospholipid, The aforementioned ether-type glycerophospholipid contains plasmalogen derived from sea squirts, The aforementioned ester-type glycerophospholipid contains phosphatidylcholine, The phosphatidylcholine content is 10 to 80% by mass relative to the total mass of the ester-type glycerophospholipid. A composition having a viscosity of less than 15,000 cps.

13. comprising an ether-type glycerophospholipid and an ester-type glycerophospholipid, The aforementioned ether-type glycerophospholipid contains plasmalogen derived from sea squirts, The ester-type glycerophospholipid contains phosphatidylethanolamine, The content of the phosphatidylethanolamine is 5 to 40% by mass relative to the total mass of the ester-type glycerophospholipid. A composition having a viscosity of less than 15,000 cps.

14. The composition according to any one of claims 1 to 13, wherein the ester-type glycerophospholipid comprises 15 to 22% by mass of phosphatidylcholine, 25 to 32% by mass of phosphatidylethanolamine, and 18 to 25% by mass of phosphatidylinositol.

15. Contents comprising the composition according to any one of claims 1 to 14, A film containing the contents, A capsule containing [the specified ingredient].

Citation Information

Patent Citations

  • Preparation of pharmaceutical compositions

    JP2002507966A

  • Method for preparing colloidal systems for the delivery of active compounds

    JP2012529458A

  • Emulsified composition and soft capsule formulation containing the same

    JP2017186320A

  • Chicken breast meat-derived plasmalogen composition having improvement effects on cognitive function, preparation method thereof and processed foods for enhancing and / or improving cognitive function manufactured by adding the same

    JP2017200466A

  • Food / drink composition and capsule agent

    JP2019146553A